Breakfast mango trial reports greater fasting glucose reductions than bread
Replacing breakfast bread with either of two mango varieties favored fasting glucose reductions in a small diabetes trial. The comparison took place within a controlled, calorie-restricted diet.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
In this small trial, replacing breakfast bread with Safeda or Dasheri mango during a calorie-restricted diet produced greater reductions in fasting blood glucose than bread. The reported advantages describe differences in glucose change over the study, rather than differences in final glucose levels. The abstract does not establish the effects of adding mango to an otherwise unchanged diet.
The trial was small and short. The abstract does not report confidence intervals or the bread portion, limiting assessment of result precision and how closely other breakfast substitutions would match this comparison.
What researchers found
Greater fasting blood glucose reductions relative to bread
Between-group differences in glucose reductions over 8 weeks, rather than differences in final glucose concentrations. Both comparisons were reported as statistically significant.
Changes versus final levels
A difference in glucose reductions compares how much each group's measurement changed. It does not give the gap between their final readings. The abstract separately reports smaller glucose reductions within the mango groups.
The dietary setting matters
Participants ate mango in place of breakfast bread while following a controlled, calorie-restricted diet. That substitution defines the question tested. The abstract cannot show whether simply adding mango, or replacing another food, would have similar effects.
The original publication
Glycemic, lipid, anthropometric and body composition responses to two Mango varieties versus white bread in people with type 2 diabetes: an 8-week randomised controlled trial.
Kehar S, Bhatt SP, Pandey RM et al.
J Diabetes Metab Disord · 2025
- PubMed ID
- 40761695
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.